Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA) downgraded to Hold from Buy at Argus by John Staszak, based on his belief that the company will have to make significant investments to expand its business going forward. 2. First Solar (FSLR) downgraded to Hold from Buy at Argus by analysts Stephen Biggar and Jasper Hellweg, citing what they see as the company's lack of earnings visibility. The analysts say that the company's backlog is falling, while it is encountering "intense price competition." 3. Palo Alto Networks (PANW) downgraded to Outperform from Strong Buy at Raymond James by analyst Michael Turits, citing the company's weaker than expected guidance for FY17. Palo guided product growth to 12%-13%, nearly halfway below the consensus estimate of 22%, said Turits, who lowered his price target for the shares to $165 from $180. 4. G-III Apparel (GIII) downgraded to Sell from Hold at Stifel. Despite the recent decline in the stock, its risk/reward ratio is unfavorable given the multiple risks faced by the company, according to Stifel analyst Jim Duffy. 5. Quest Diagnostics (DGX) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).

UBS raised the firm's price target on Quest Diagnostics to $146 from $139 and keeps a Neutral rating on the shares. UBS is more confident that Quest can hit its margin expansion story following the Q2 print and the firm's call with management, the analyst tells investors in a research note. Labor cost trends seem to have already peaked and Covid revenues should no longer be a headwind starting 2H, while above market base volume growth continues, the firm notes.

Citi raised the firm's price target on Quest Diagnostics to $145 from $135 and keeps a Neutral rating on the shares post the Q1 report. The company increased the midpoint of its fiscal 2024 revenue target and management anticipates the rest of fiscal year to follow regular seasonality on a revenue and margin basis with a step-up into Q2, the analyst tells investors in a research note.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

As previously reported, Evercore ISI analyst Sean Morgan upgraded First Solar to Outperform from In Line with an unchanged price target of $227. The market is expecting the Biden administration to remove a trade exemption for bifacial solar modules imported to the U.S., which now represent about 98% of U.S. solar imports, the analyst noted. Solar panel imports skyrocketed in 2023 to 54GW and some market participants have stated that reliance on imports and oversupply are negatively impacting solar domestic factories, which have been a priority for the current U.S. administration, putting pressure on greater U.S. trade protections and policy support, the analyst added.

Evercore ISI analyst Sean Morgan upgraded First Solar to Outperform from In Line with a $227 price target.